- Home
- BEAM vs BTE Comparison
BEAM vs BTE Comparison
Compare BEAM & BTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- BTE
- Stock Information
- Founded
- BEAM 2017
- BTE 1993
- Country
- BEAM United States
- BTE Canada
- Employees
- BEAM N/A
- BTE N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- BTE Meat/Poultry/Fish
- Sector
- BEAM Health Care
- BTE Consumer Staples
- Exchange
- BEAM Nasdaq
- BTE Nasdaq
- Market Cap
- BEAM 1.7B
- BTE 1.6B
- IPO Year
- BEAM 2020
- BTE N/A
- Fundamental
- Price
- BEAM $21.08
- BTE $2.37
- Analyst Decision
- BEAM Strong Buy
- BTE Hold
- Analyst Count
- BEAM 10
- BTE 1
- Target Price
- BEAM $48.56
- BTE $5.50
- AVG Volume (30 Days)
- BEAM 2.9M
- BTE 19.5M
- Earning Date
- BEAM 11-04-2025
- BTE 10-30-2025
- Dividend Yield
- BEAM N/A
- BTE 2.71%
- EPS Growth
- BEAM N/A
- BTE N/A
- EPS
- BEAM N/A
- BTE 0.34
- Revenue
- BEAM $60,272,000.00
- BTE $2,318,087,632.00
- Revenue This Year
- BEAM N/A
- BTE N/A
- Revenue Next Year
- BEAM $17.95
- BTE N/A
- P/E Ratio
- BEAM N/A
- BTE $6.78
- Revenue Growth
- BEAM N/A
- BTE N/A
- 52 Week Low
- BEAM $13.53
- BTE $1.36
- 52 Week High
- BEAM $35.25
- BTE $3.45
- Technical
- Relative Strength Index (RSI)
- BEAM 62.10
- BTE 66.60
- Support Level
- BEAM $19.57
- BTE $2.10
- Resistance Level
- BEAM $21.59
- BTE $2.44
- Average True Range (ATR)
- BEAM 1.24
- BTE 0.09
- MACD
- BEAM 0.47
- BTE 0.02
- Stochastic Oscillator
- BEAM 91.11
- BTE 80.88
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.